Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
5,555,556
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
499,811
-
Shares change
-
+22,439
-
Total reported value, excl. options
-
$1,484,978
-
Value change
-
-$7,405
-
Number of buys
-
8
-
Number of sells
-
-8
-
Price
-
$2.97
Significant Holders of Lipocine Inc. - Common Stock, par value $0.0001 per share (LPCN) as of Q3 2023
25 filings reported holding LPCN - Lipocine Inc. - Common Stock, par value $0.0001 per share as of Q3 2023.
Lipocine Inc. - Common Stock, par value $0.0001 per share (LPCN) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 499,811 shares
of 5,555,556 outstanding shares and own 9% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (221,459 shares), BlackRock Inc. (74,846 shares), TWO SIGMA ADVISERS, LP (56,922 shares), GEODE CAPITAL MANAGEMENT, LLC (48,854 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (25,329 shares), WEALTH EFFECTS LLC (18,761 shares), STATE STREET CORP (18,626 shares), Kestra Advisory Services, LLC (16,703 shares), RENAISSANCE TECHNOLOGIES LLC (15,597 shares), and Cutler Group LLC / CA (765 shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.